SF Healthcare Week: Recursion Co-Founder & CEO Chris Gibson talks the Exscientia merger, Recursion's scale and capabilities, and key targets in development

blonca9
Jan 15
1 min read

He discusses the merger that completed towards the end of last year, Recursion's computational and wet lab abilities, cerebral cavernous malformation, targets such as MALT1, LSD1, CDK7, and more.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

SF Healthcare Week: Recursion Co-Founder & CEO Chris Gibson talks the Exscientia merger, Recursion's scale and capabilities, and key targets in development

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight